Themes
Business
Talent
At the park
Communities
Jobs & internships
Events
News
Contact
What to expect?
You will receive information and insights on all the different parts of RegMed XB. From our moonshots, valorisation to the RegMed XB Pilot Factory. But there’s more! The RegMed XB Annual Conference 2023 brings you two powerful days of interaction, learning and inspiration. It is THE network opportunity for everyone involved in science, business and innovations in the Regenerative Medicine field.
The underlying theme of the conference is: together we make the impossible possible. We invite you all to gather in order to connect, learn and discuss. There will be interesting keynotes on various topics, including valorisation, ethics, business development, regulatory and much more.
The RegMed XB Annual Conference is the closing event of the Life Sciences & Health week at the Leiden Bio Science Park from 22nd to 29th June 2023.
About RegMed XB
We are RegMed XB, an ambitious and successful public-private collaboration in the Netherlands and Flanders. Our goal is to bring affordable regenerative medicine solutions to patients with chronic conditions.
On this journey “from care to cure”, regenerative medicine continues to cross borders. We are shooting for the moon, with boundless ambitions.
We would very much like to share our ambition and knowledge with you and show you the opportunities of the promising field of regenerative medicine.
Join the Annual Conference 2023
As of June, the Leiden Bio Science Park team has been joined by Gerwin Zomer, who steps into the role of Account Manager Physical Living Environment. To get to know him a bit...
Researchers at the Leiden University Medical Center (LUMC) have announced promising early results from a clinical trial using lab-grown insulin-producing islet cells derived from...
VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.